Audit: QRS - Microdosing LSD Analogues for Health & Longevity

Audit conducted on 30/09/2026 09:23 using AI4L + evidence-mcp / Opus 5.5

Iterations

Summary

Items Count
Total 94
Passed 86
Failed 0
N/A 8
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 At-a-glance, protocol, time-to-effect, tiers, gates, markers and qualitative items each trace to ER text (Conclusion, Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks, Key Interactions, Monitoring)
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Cautious phrasing kept, e.g. ‘long-term effects remain unknown’, ‘lasting gains have not held up’, ‘not confirmed against placebo’
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No claim strengthened or softened; contraindications and tiers match ER
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Facts surfaced under their ER categories; modifying factors not relabelled as risks or cautions
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 Only ‘Fadiman’ appears, as in the ER protocol label; no PMIDs, NCT IDs or brand names
1.6 The QRS does not introduce new attributions. 🟢 No new attributions

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Tone mirrors the ER’s measured, evidence-weighted framing
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢  
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No direct address found
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms limited to ER labels and named drug classes with examples
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 It DOES NOT address the reader directly 🟢  
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢  
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 No ‘anti-aging’ wording
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢 No lay route or consumer-grade terms found

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” Gate headings: “Contraindications”, “Key Interactions” Tier labels: “High”, “Medium”, “Low”, “Speculative” Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed headings, tier labels and column headers unchanged
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All template data-qrs-var spans present; marker_# and qualitative_item_# expanded to 8 and 6 instances
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Non-variable spans (website=evidence_review, audit, full_review) unchanged

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No mapped ER section is empty; empty tiers (High benefits, Medium risks) are hidden per 12.5/13.5
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels ‘Community protocol (Fadiman)’, ‘Analogue dose equivalence’, ‘Best time of day’ match ER bold labels verbatim
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Time-to-effect labels lifted from ER Practical Considerations wording
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji found
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Sections condensed relative to the ER; no content extended onto a second page

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢  
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 duration quoted because it contains a colon
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢  
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 26.9.29 matches QRS.md
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 2026-0930-0904
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢  
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢  
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢  
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 Opus 5.5
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 ‘Microdosing LSD Analogues for Health & Longevity - Quick Reference Sheet’
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 09/30/2026
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Opus 5.5
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 Opens by describing the practice (small repeated doses of unregulated chemical relatives of LSD, mostly converted to LSD) and its purpose (mood or focus)
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses ER Conclusion paragraphs 1-3
7.3 [at_a_glance] is no longer than 70 words 🟢 70 words
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢  
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Only ‘LSD’, a term non-specialists use and understand
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢  
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢 All 9 ER ‘Populations who should avoid’ items present
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 ER em-dash clause for valve disease recast as a parenthetical qualifier; no trailing clauses
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Thresholds kept (140/90 mmHg, moderate or greater regurgitation or stenosis, under 18, on dosing days)
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A No ranking notation in the ER
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 Section populated; ER names populations to avoid
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section not empty

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 13 interactions; lithium correctly excluded as it is a contraindication
9.3 Individual [caution_items] are formatted as <li></li> 🟢  
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example drug lists preserved
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A No ranking notation in the ER
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 Section populated
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section not empty

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Schedule and dose, analogue dose equivalence, time of day
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three actionable aspects exist in the ER
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Following-night sleep, 8-week depression scores, acute onset/peak/offset
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Medium-tier sleep benefit first, then Low-tier items
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three time-to-effect aspects exist in the ER
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect information

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Items reduced to ER headings
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 benefits_high set to display: none (ER: no benefit reaches High)

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Mechanistic suffix of the valve-disease heading stripped
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 risks_medium set to display: none (ER: no risk reaches Medium)

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢  
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All 8 ER table biomarkers listed with ER targets
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢  

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢  
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All 6 ER qualitative markers listed

Issues 30/09/2026 09:23

Pass rate 100.00%. No issues found.

Issues 30/09/2026 09:16

  1. 1.2 — Heart-valve caution qualifier dropped: At-a-Glance (QRS line 433) says heart-valve problems “bring serious dangers” but omits the ER Conclusion’s cautious qualifier “where long-term effects remain unknown” (ER line 466), overstating a risk the ER rates Speculative.

Fixes 30/09/2026 09:16

  1. 1.2 — Heart-valve caution qualifier restored: Rewrote the At-a-Glance final sentence to carry the ER’s “long-term effects remain unknown” for heart-valve problems and restored the ER order of risk groups, trimming wording elsewhere to stay at 70 words.

Issues 30/09/2026 09:13

  1. 13.3 — Mechanism kept in risk item: The Speculative risk at line 592 reads “Heart-valve disease from chronic 5-HT2B activation”; the clause “from chronic 5-HT2B activation” is a mechanistic explanation that 13.3 requires stripping.

Fixes 30/09/2026 09:13

  1. 13.3 — Mechanism removed from risk: Changed the Speculative risk item from “Heart-valve disease from chronic 5-HT2B activation” to “Heart-valve disease”, stripping the mechanistic clause.

Issues 30/09/2026 09:10

  1. 11.2 — Time-to-effect sets misordered: time_2 “Acute effects” (line 494), whose onset/peak/offset window the ER describes under the Perceptible Intoxication risk, is placed ahead of time_3 “Depression scores” (line 505), which ties to an ER benefit with a larger reported magnitude (59.5% MADRS reduction in the open-label trial).

Fixes 30/09/2026 09:10

  1. 11.2 — Time-to-effect sets reordered: Swapped time_2 and time_3 so “Depression scores / 8 weeks” (the benefit-linked set) now comes second and “Acute effects / About 1 hour” third.

Issues 30/09/2026 09:05

  1. 1.2 — Conversion hedge dropped: action_2_sub (line 461) omits the ER’s “assuming complete conversion” qualifier from the Analogue dose equivalence bullet, presenting the 11–13 µg equivalence unconditionally.
  2. 7.2 — High-risk groups missing: at_a_glance (line 433) omits the Conclusion’s execution-critical point that serious dangers concentrate in people taking lithium, with a personal or family history of psychosis or bipolar disorder, or with heart-valve problems.

Fixes 30/09/2026 09:05

  1. 1.2 — Conversion hedge restored: Added “assuming complete conversion” to action_2_sub, matching the ER Analogue dose equivalence bullet.
  2. 7.2 — High-risk groups added: Rewrote at_a_glance (70 words) to add that lithium use, heart-valve problems and a personal or family psychosis or bipolar history bring serious dangers, condensing other phrasing to stay within the word limit.